NVO241018C150000
- 0.03
- 0.000.00%
Novo-Nordisk A/S Newsroom
eli lilly and co (LLY.US) shifts investment focus to europe, investing 0.36 billion US dollars in the biotechnology sector in the united kingdom.
The pharmaceutical giant will also study the promotion of anti-obesity drugs in the united kingdom; the Labour government in the united kingdom is trying to attract more foreign investment.
Weight Loss Drugs Have One Big Issue; These Companies Want to Fix It
The good news for the obese population in the USA: FDA is considering allowing the combination version of eli lilly and co (LLY.US) weight loss drug.
(FDA) agreed on Friday to reconsider the decision made last month, which banned private drug compounders from selling their own compounded versions of eli lilly and co's weight loss and diabetes treatment drugs.
Criminal Networks Cash In On Demand For Weight Loss Drugs, Authorities Say
European Equities Traded in the US as American Depositary Receipts Ends Week Higher in Friday Trading
Lilly Expects Zepbound Approval in Japan by Mid-2025: Report
Sector Update: Health Care Stocks Edge Higher Pre-Bell Friday
Express News | Weight loss drug manufacturer Zealand Pharma: the company is targeting the "next generation" of weight loss drugs.
Update: Senator Warren Asks US Antitrust Regulator to 'Carefully Scrutinize' Novo Nordisk's Bid for Catalent
Novo Nordisk to Bolster Leadership Team, Workforce in India
Here's What Dragged Novo Nordisk A/S (NVO) in Q3
Market Chatter: Novo Nordisk Partners With AI Start-ups, Plans to Boost Headcount in India
Are the side effects of GLP-1 drugs too severe? Danish pharmaceutical company Zealand is advancing the "next generation of weight loss drugs".
①Although novo-nordisk a/s and eli lilly and co's drugs are very effective in weight loss, the side effects they bring should not be ignored, including significant muscle loss and increased suicidal thoughts; ②Danish pharmaceutical company Zealand stated that a weight loss drug they are currently developing has higher weight loss quality - less muscle loss and fewer side effects.
Danish weight-loss drug newcomer accelerates the promotion of the "next generation weight-loss drug". Will the monopoly of "Norley" be broken?
Novo Nordisk and Eli Lilly's strong competitor Zealand Pharma announced the heavyweight launch of its obesity drug substitute: this is our "imperium crown gem".
U.S. stocks closed: The three major indexes are "unconcerned" about the bearish data, with Chinese concept stocks rebounding after the decline.
①Both inflation and unemployment data exceeded expectations, leading to a slight decline in the three major US stock indexes; ②The Nasdaq China Golden Dragon Index stabilized and rebounded; ③AMD released a competitor to nvidia in the AI chip market, causing a drop in stock price; ④A weight loss platform offering a "budget version of GLP-1 medication" saw continuous stock price increases, with analysts warning of risks.
WW Surge After GLP-1 Compounding Announcement Not Justified After Study, Barclay Says
Sector Update: Health Care Stocks Retreat Thursday Afternoon
Novo Holdings to Acquire Majority Stake in Stingray Marine Solutions, a Leading Provider of Aquaculture Technology
FTC Faces Pressure to Block Novo Nordisk-Catalent Merger Over Antitrust Fears
Eli Lilly Issues Cease-And-Desist Letters to Compounders Over Weight-Loss Drug Copies As Shortage Resolves